AIM
ANIK icon

Alambic Investment Management’s Anika Therapeutics ANIK Stock Holding History

Alambic Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-18,559
Closed -$624K – 346
2018
Q4 		$624K Buy
+18,559
New +$670K 0.26% 140
2018
Q3 		– Sell
-19,400
Closed -$621K – 279
2018
Q2 		$621K Buy
+19,400
New +$799K 0.17% 180

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Alambic Investment Management's ANIK Position: Q1 2019 in Review

Alambic Investment Management sold out of Anika Therapeutics (ANIK) in Q1 2019, closing a stake of 18,559 shares — an estimated $624K sold.

Alambic Investment Management first reported a position in ANIK in Q2 2018 and held it in 2 quarters. The position peaked at $624K in Q4 2018. 157 funds tracked by Wall St. Rank hold ANIK as of Q1 2019.

  • Alambic Investment Management reported no remaining Anika Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Alambic Investment Management sold 18,559 Anika Therapeutics shares in Q1 2019, an estimated $624K.
  • Alambic Investment Management first reported a position in Anika Therapeutics in Q2 2018 and held it in 2 quarters.
  • Alambic Investment Management's Anika Therapeutics position peaked at $624K in Q4 2018.
  • 157 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2019.

Based on Alambic Investment Management's 13F filing for Q1 2019, filed 9 May 2019.